Congressional Legislators Agree With Nuvilex's Dr. Mark Rabe on Reclassifying Marijuana

NEW YORK, NY--(Marketwired - Feb 14, 2014) - Nuvilex, Inc.'s (OTCQB: NVLX) Dr. Mark L. Rabe has something in common with 18 members of Congress. All of them want marijuana reclassified from its current listing as a dangerous drug with no medical value, and they want President Obama to use his authority to make that change by removing marijuana from the Schedule I category. Currently marijuana is viewed in the same category as drugs like heroin and LSD, and in a letter sent to the president this week, 18 legislators said this status "makes no sense."

In the letter to President Obama, the 18 members of Congress said, "We request that you instruct Attorney General Holder to delist or classify marijuana in a more appropriate way, at the very least eliminating it from Schedule I or II."

Nuvilex appointed Dr. Rabe, a leading figure in the medical marijuana field, as the Chairman of the Scientific Advisory Board of Medical Marijuana Sciences, the company's wholly-owned subsidiary formed to house its work in the Cannabis industry. 

Dr. Rabe agrees with the letter to the president. "The most important component of legalization is that the Cannabis plant and its medicinal cannabinoid components need to be removed from the federal "Schedule I" category. Because of this designation, doctors currently cannot legally treat patients with cannabinoids. Rather, they can only "recommend" the use of medical marijuana, which leaves patients on their own to obtain their own medicine and treat themselves."

The Congressional letter went on to state, "Classifying marijuana as Schedule I at the federal level perpetuates an unjust and irrational system. Schedule I recognizes no medical use, disregarding both medical evidence and the laws of nearly half of the states that have legalized medical marijuana."

Dr. Rabe realizes this is the first step to Nuvilex beginning its work with Cannabis and added, "Removal of the Schedule I designation would also allow for properly designed placebo-controlled double blind studies to occur in order to advance the use of cannabinoids as medicine."

About Stock Market Media Group

SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. For more information and to read disclaimers and disclosures: www.stockmarketmediagroup.com.